Kineta updates KVA12123 clinical results from ongoing Phase 1/2 VISTA101 study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 08 2024
0mins
Should l Buy ?
Clinical Trial Update: Kineta presented positive results from its VISTA-101 Phase 1/2 clinical trial for KVA12123, an anti-VISTA monoclonal antibody, showing it was well tolerated with no dose limiting toxicities and promising outcomes in patients with advanced solid tumors, including stable disease in several cases.
Collaboration and Future Plans: Kineta has entered into a collaboration agreement with TuHURA Biosciences, receiving a $5 million payment and reopening enrollment in the VISTA-101 trial, while continuing to work together on the clinical program.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
